O Brien Greene & Co. Inc Takes Position in Medpace Holdings, Inc. (NASDAQ:MEDP)

O Brien Greene & Co. Inc bought a new stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund bought 12,837 shares of the company's stock, valued at approximately $4,265,000. Medpace accounts for approximately 1.4% of O Brien Greene & Co. Inc's portfolio, making the stock its 29th largest holding.

Several other institutional investors and hedge funds have also bought and sold shares of the stock. Ieq Capital LLC boosted its holdings in Medpace by 1,090.6% in the fourth quarter. Ieq Capital LLC now owns 27,206 shares of the company's stock worth $9,039,000 after acquiring an additional 24,921 shares in the last quarter. Private Advisor Group LLC raised its position in shares of Medpace by 53.8% during the fourth quarter. Private Advisor Group LLC now owns 2,227 shares of the company's stock worth $740,000 after purchasing an additional 779 shares during the period. Alberta Investment Management Corp lifted its holdings in shares of Medpace by 15.3% in the 4th quarter. Alberta Investment Management Corp now owns 4,447 shares of the company's stock worth $1,477,000 after purchasing an additional 589 shares in the last quarter. Kestra Investment Management LLC grew its position in Medpace by 58.3% in the 4th quarter. Kestra Investment Management LLC now owns 1,105 shares of the company's stock valued at $367,000 after purchasing an additional 407 shares during the period. Finally, Venturi Wealth Management LLC increased its stake in Medpace by 602.0% during the 4th quarter. Venturi Wealth Management LLC now owns 344 shares of the company's stock valued at $114,000 after purchasing an additional 295 shares in the last quarter. 77.98% of the stock is owned by institutional investors.

Remove Ads

Wall Street Analyst Weigh In

Separately, Robert W. Baird raised their price objective on shares of Medpace from $354.00 to $362.00 and gave the company a "neutral" rating in a research note on Monday, January 27th. Seven equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of "Hold" and an average price target of $381.44.

Medpace Trading Up 1.3 %

Shares of MEDP traded up $4.35 during trading hours on Monday, reaching $344.57. 177,383 shares of the stock traded hands, compared to its average volume of 274,190. Medpace Holdings, Inc. has a 52 week low of $302.01 and a 52 week high of $459.77. The company has a market cap of $10.50 billion, a price-to-earnings ratio of 27.30, a PEG ratio of 3.81 and a beta of 1.36. The stock has a fifty day simple moving average of $343.13 and a 200 day simple moving average of $346.83.

Medpace (NASDAQ:MEDP - Get Free Report) last posted its earnings results on Monday, February 10th. The company reported $3.67 EPS for the quarter, topping the consensus estimate of $2.96 by $0.71. Medpace had a net margin of 19.17% and a return on equity of 51.48%. Analysts predict that Medpace Holdings, Inc. will post 12.29 earnings per share for the current fiscal year.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.